Fedratinib

Major

Fedratinib Acetaminophen And Codeine Capital® & Codeine Explained Increased CYP3A4/CYP2D6 substrate exposure Details Fedratinib Clindamycin ANTIROBE Explained Increased CYP3A4 substrate exposure Details Fedratinib Omeprazole Gastrobim Explained Increased CYP3A4/CYP2C19 substrate exposure Details Fedratinib Amitriptyline Elavil Explained Increased CYP2D6 substrate exposure Details Fedratinib Colchicine Colcrys Explained Increased CYP3A4 substrate exposure Details Fedratinib Simvastatin Flolipid Explained Increased CYP3A4 substrate exposure Details Fedratinib Abatacept Injection Orencia An increased risk of infection Details Fedratinib Abemaciclib Verzenio Explained Increased CYP3A4 substrate exposure Details Fedratinib Acalabrutinib Calquence Increased CYP3A4 substrate exposure Details Fedratinib Apixaban Eliquis Explained Increased CYP3A4 substrate exposure Details Fedratinib Aripiprazole Injection Abilify Increased CYP3A4/CYP2D6 substrate exposure Details Fedratinib Avapritinib Ayvakit Increased CYP3A4 substrate exposure Details Fedratinib Avatrombopag Doptelet Increased CYP3A4 substrate exposure Details Fedratinib Belumosudil Rezurock Explained Increased CYP3A4 substrate exposure Details Fedratinib Atorvastatin Atorvaliq Increased CYP3A4 substrate exposure Details Fedratinib Abatacept Orencia Explained An increased risk of infection Details Fedratinib Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Fedratinib Abiraterone Abirtega Increased CYP3A4 substrate exposure Details Fedratinib Alfuzosin UroXatral Increased CYP3A4 substrate exposure Details Fedratinib Amlodipine Amvaz® Increased CYP3A4 substrate exposure Details Fedratinib Avanafil Stendra Increased CYP3A4 substrate exposure Details Fedratinib Axitinib Inlyta Increased CYP3A4 substrate exposure Details Fedratinib Baricitinib Olumiant An increased risk of infection Details Fedratinib Bedaquiline Sirturo Increased CYP3A4 substrate exposure Details Fedratinib Bosutinib Bosulif Increased CYP3A4 substrate exposure Details Fedratinib Brexpiprazole Rexulti Increased brexpiprazole exposure Details Fedratinib Brigatinib Alunbrig Increased CYP3A4 substrate exposure Details Fedratinib Budesonide Entocort Increased CYP3A4 substrate exposure Details Fedratinib Budesonide Nasal Spray Rhinocort Increased CYP3A4 substrate exposure Details Fedratinib Budesonide Oral Inhalation Pulmicort Increased CYP3A4 substrate exposure Details Fedratinib Cabozantinib Cabometyx Increased CYP3A4 substrate exposure Details Fedratinib Cabozantinib (Thyroid Cancer) Cabometyx Increased CYP3A4 substrate exposure Details Fedratinib Capmatinib Tabrecta Increased CYP3A4 substrate exposure Details Fedratinib Clindamycin Injection ANTIROBE Increased CYP3A4 substrate exposure Details Fedratinib Clindamycin Topical C/T/S® Increased CYP3A4 substrate exposure Details Fedratinib Clindamycin Vaginal Cleocin Increased CYP3A4 substrate exposure Details Fedratinib Cobimetinib Cotellic Increased CYP3A4 substrate exposure Details Fedratinib Cyclosporine Injection Atopica Increased CYP3A4 substrate exposure Details Fedratinib Cyclosporine Ophthalmic Cequa Increased CYP3A4 substrate exposure Details Fedratinib Dalfampridine Ampyra Increased dalfampridine exposure and an increased risk of dalfampridine-related adverse events Details